Hemophilia A and B Pathophysiology

Understanding hemophilia is essential for any aspiring clinician because it represents a classic model of inherited coagulation disorders, tying together genetics, molecular biology, laboratory diagnostics, and targeted therapeutics. Mastery of this topic not only prepares you for exam questions but also builds a framework for approaching other bleeding diatheses. You will learn to distinguish between these two conditions, interpret critical lab tests, and understand the rationale behind modern treatment strategies.

The Genetic Blueprint: X-Linked Recessive Inheritance

Hemophilia A and B are both X-linked recessive disorders. This means the genes responsible for producing the clotting factors are located on the X chromosome. Since males have only one X chromosome (karyotype 46,XY), a single defective gene on that X chromosome is sufficient to cause the disease. Females (46,XX) have two X chromosomes; they are typically asymptomatic carriers unless they inherit two defective alleles, which is exceedingly rare.

The inheritance pattern has clear clinical implications. A father with hemophilia will pass his affected X chromosome to all his daughters, making them obligate carriers. He will pass his Y chromosome to his sons, who will be unaffected. A carrier mother has a 50% chance of passing the affected X to a son (who will have hemophilia) and a 50% chance of passing it to a daughter (who will be a carrier). This pattern explains why hemophilia is almost exclusively seen in males, while females act as genetic conduits.

Molecular Deficiency and the Coagulation Cascade

The core defect in hemophilia is a deficiency of specific coagulation factors that are crucial for the intrinsic pathway of the clotting cascade. It is vital to visualize the cascade as a series of amplifications: a small trigger leads to a massive generation of thrombin and, ultimately, a stable fibrin clot.

Hemophilia A is caused by a deficiency or dysfunction of Factor VIII (FVIII). Think of Factor VIII as the critical cofactor for Factor IX. In the intrinsic pathway, Factor IXa (activated) teams up with Factor VIIIa on a phospholipid surface to form the "tenase complex." This complex is incredibly efficient at activating Factor X, which then proceeds down the common pathway.

Hemophilia B, sometimes called Christmas disease, is caused by a deficiency or dysfunction of Factor IX (FIX). Without adequate Factor IX, the tenase complex cannot form properly, stalling the cascade at the same point as Hemophilia A. Despite affecting different proteins, the final common pathway—a failure to efficiently generate Factor Xa—is identical, which is why their clinical presentations are nearly indistinguishable.

Clinical Vignette: A 2-year-old boy is brought in after a minor fall. He has significant swelling and pain in his right knee. His mother mentions he bruises easily. This presentation of hemarthrosis (bleeding into joint spaces) is a hallmark of severe hemophilia, often appearing with early ambulation.

Clinical Presentation: The Pattern of Bleeding

The bleeding phenotype in hemophilia is distinct from platelet disorders. Deficiencies in the intrinsic pathway lead to delayed, deep tissue bleeding rather than immediate superficial bleeding. Key presentations include:

• Hemarthrosis: Recurrent bleeding into weight-bearing joints (knees, ankles, elbows) is the most common manifestation. This causes pain, swelling, and, over time, can lead to crippling arthropathy.
• Deep Muscle Hematomas: Bleeding into the iliopsoas or forearm compartments can be life-threatening due to compartment syndrome or significant blood loss.
• Prolonged Bleeding After Surgery or Trauma: Bleeding may not be immediate but can persist for hours or days after an injury or dental extraction.
• Other serious sites include intracranial hemorrhage, retroperitoneal bleeding, and hematuria.

The severity of the disease is directly related to the residual level of circulating factor:

• Severe: <1% factor activity. Presents with spontaneous bleeding.
• Moderate: 1-5% factor activity. Bleeding with minor trauma.
• Mild: 5-40% factor activity. May only bleed with major surgery or severe trauma.

Laboratory Diagnosis and Interpretation

Diagnosing hemophilia relies on a logical, stepwise interpretation of coagulation tests. This is a classic laboratory puzzle you must be able to solve.

1. Prolonged Activated Partial Thromboplastin Time (PTT or aPTT): The PTT test measures the function of the intrinsic and common pathways. A deficiency in Factor VIII or IX will prolong the PTT.
2. Normal Prothrombin Time (PT): The PT test measures the function of the extrinsic and common pathways. It is normal in hemophilia because Factor VII (extrinsic) and the common pathway factors (X, V, II, fibrinogen) are unaffected.
3. Normal Bleeding Time: This test assesses platelet function and primary hemostasis (the initial platelet plug). It is normal in hemophilia, distinguishing it from disorders like von Willebrand disease or platelet defects, where bleeding is more superficial (mucocutaneous).

The most critical confirmatory test is the mixing study. When a patient's plasma with a prolonged PTT is mixed 1:1 with normal pooled plasma (which contains all factors), the PTT should correct to normal if the cause is a simple factor deficiency (like hemophilia). If the PTT does not correct, it suggests the presence of an inhibitor (like an autoantibody against Factor VIII), which is a major complication of treatment. This test elegantly distinguishes a deficiency from an inhibitor.

Principles of Management and Treatment

Treatment revolves around replacing the missing factor to achieve hemostasis. The approach is stratified by severity and clinical scenario.

Factor Replacement Therapy is the cornerstone for both Hemophilia A and B. This involves intravenous infusion of:

• For Hemophilia A: Plasma-derived or recombinant Factor VIII concentrate.
• For Hemophilia B: Plasma-derived or recombinant Factor IX concentrate.

Dosing is calculated based on desired peak level, body weight, and the factor's half-life (FVIII: ~12 hours; FIX: ~24 hours). Treatment can be given "on-demand" for active bleeding or "prophylactically" to prevent bleeding episodes, especially in severe cases.

A unique therapy for mild Hemophilia A is Desmopressin (DDAVP). This synthetic analog of vasopressin stimulates the release of stored von Willebrand factor and Factor VIII from endothelial cells. It can transiently raise a mild hemophiliac's Factor VIII level 2- to 4-fold, sufficient for minor procedures or bleeding episodes. It is not effective for Hemophilia B.

Clinical Vignette: An 18-year-old male with known mild Hemophilia A needs a wisdom tooth extraction. His baseline Factor VIII is 12%. The plan would likely involve administering DDAVP one hour prior to the procedure to boost his Factor VIII to a hemostatic level (>30-50%) for the perioperative period.

Common Pitfalls

1. Confusing the inheritance pattern. Remember: X-linked recessive means male predominance. A father cannot pass the disease to his sons (he gives them a Y chromosome), but all his daughters will be carriers. A common test trap is to show a pedigree where an affected male has an unaffected son—this should immediately tell you the disorder is not X-linked recessive.
2. Mistaking the lab profile. A classic distractor is presenting a patient with a prolonged PT and normal PTT, which points to Factor VII deficiency or warfarin use, not hemophilia. Hemophilia is a prolonged PTT with a normal PT. Also, remember the bleeding time is normal.
3. Misapplying desmopressin. Desmopressin is only useful for mild Hemophilia A. It will not work for moderate/severe Hemophilia A (no stored factor to release) or for any severity of Hemophilia B (it does not affect Factor IX). Using it in the wrong context is an ineffective intervention.
4. Overlooking inhibitors. After years of treatment, some patients develop neutralizing antibodies (inhibitors) against the replaced factor. A key clue is a patient whose bleeding becomes unresponsive to standard factor doses. The lab clue is a mixing study that fails to correct the prolonged PTT.

Summary

• Hemophilia A (Factor VIII deficiency) and Hemophilia B (Factor IX deficiency) are X-linked recessive disorders presenting almost exclusively in males with deep tissue bleeding like hemarthrosis and deep muscle hematomas.
• The laboratory hallmark is an isolated prolonged PTT with a normal PT and normal bleeding time. A mixing study corrects the PTT, confirming a factor deficiency rather than an inhibitor.
• The severity of clinical bleeding correlates directly with the residual factor activity level (severe: <1%, mild: 5-40%).
• Treatment is centered on factor replacement (FVIII for A, FIX for B). Desmopressin can be used to transiently boost Factor VIII levels in patients with mild Hemophilia A.
• Always be alert for the development of inhibitors (antibodies), which are a major treatment complication and are suggested by a mixing study that does not correct.